Loading...
Loading...
SAGE| Name | Value |
|---|---|
| Revenues | 11.9M |
| Cost of Revenue | 5.3M |
| Gross Profit | 6.6M |
| Operating Expense | 107.8M |
| Operating I/L | -101.2M |
| Other Income/Expense | 7.7M |
| Interest Income | 7.6M |
| Pretax | -93.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -93.6M |
Sage Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of medicines for central nervous system disorders. Its lead product, ZULRESSO, targets postpartum depression in adults. The company's pipeline includes zuranolone, a neuroactive steroid in Phase III trials for various mood disorders, and SAGE-324, a compound in Phase II trials for essential tremors and neurological conditions. Additionally, SAGE-718, an NMDA receptor modulator, has completed Phase I trials for multiple conditions. Sage Therapeutics has strategic collaborations for global commercialization and development. Its revenue is generated through the sale of these pharmaceutical products and through partnerships with other pharmaceutical companies.
